Latest / Decera Clinical Education Oncology Podcast
Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma
In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:
How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL?
Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?
How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?
How should physicians sequence CAR T-cell therapy vs BTK inhibitors in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.